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NUCLEIC ACID ENCODING HUMAN REV1
PROTEIN

nation of polypeptides that are involved in causing muta
tions that lead to the formation of tumors and further
mutations that cause metastasis to occur.

RELATED APPLICATIONS
SUMMARY OF THE INVENTION

This application claims priority from Us. Provisional
Application Serial No. 60/162,140, ?led Oct. 29, 1999,

Applicants have isolated a full-length cDNA representing
the homologue of the yeast Rev1 mutagenesis protein.

incorporated herein by reference.

dyl (dCMP) transferase activity. The present invention also

Applicants also determined the chromosomal location of the
human REV1 gene and demonstrated its ubiquitous expres
sion in various human tissues. Furthermore, Applicants have
demonstrated that the human REV1 protein is a dCMP
transferase capable of inserting a dCMP opposite a template

provides methods for expressing the gene, and cancer treat

AP site.

FIELD OF THE INVENTION

The present invention relates to the cloning and expres
sion of a human gene encoding a protein having deoxycyti

ing methods using inhibitors to the gene.

10

15

BACKGROUND OF THE INVENTION

DNA damage can lead to mutations during replication. In
the yeast S. cerevisiae, it appears that the majority of
induced mutations are generated through the damage

induced mutagenesis pathWay (1,2). The required yeast

20

The present invention also relates to antibodies, including
monoclonal or polyclonal antibodies, and antibody frag
ments that have speci?c interaction With epitopes present on
hREV1. The present invention is also directed to methods of
preventing, treating, or ameliorating a disease condition or
disorder in an individual comprising the step of administer
ing a therapeutically effective amount of hREV1 protein or

genes in this pathWay include: RAD6, RAD18, REV1,
REV3, REV6, REV7, and NGM2 (1—7), most of Which have

its inhibitor or activator to the individual. The present
invention is also directed to methods or protocols in treat

been isolated by gene cloning. As expected, inactivating

ment or prevention of a disease or disorder based on the gene

these mutagenesis genes dramatically decreases the muta

tion frequency folloWing DNA damage (3,8).

25

The present invention is related to an isolated nucleic acid
molecule that encodes:
a polynucleotide Which encodes the polypeptide set forth

Rad6 is a ubiquitin-conjugating enZyme (9) and forms a

complex With Rad18 (10—12). It has been proposed that this
complex may play an important role in the initial steps of the

damage-induced mutagenesis pathWay (10). Rev3 protein is

in Table 1;
30

a DNA polymerase (DNA polymerase <Q) capable of trans
lesion DNA synthesis (13). In contrast to the replicative
DNA polymerases, deletion of the yeast REV3 gene does not
lead to lethality
Hence, this polymerase is speci?cally

required for damage-induced mutagenesis in yeast. Rev1

35

deoxycytidyl (dCMP) transferase activity in a template
dependent reaction, Which can ef?ciently insert a dCMP

opposite a template AP (apurinic/apyrimidinic) site (15).
40

of the UmuC family (14,16,17). HoWever, unlike Rev1,
Rad30 is not a component of the damage-induced mutagen
esis pathWay, but appears to be involved in a novel error-free

lesion bypass mechanism (16,17). Most recently, Rad30 Was
shoWn to be a nonessential DNA polymerase (pol 11) capable

45

50

comprises a DNA encoding the polypeptide
sequence of Table 1.
The present invention is further directed to a vector,

comprising:
55

a replicable vector; and
the above-describe polynucleotide inserted into said vec
tor.

The present invention is also directed to polypeptides
encoded by the nucleic acid described above.
The present invention is related to a pharmaceutical
60

standing the damage-induced mutagenesis pathWay in

composition comprising:
a therapeutically effective amount of an inhibitor to the

above described polypeptide; and

humans is a key to the understanding of carcinogenesis.

Isolating the human mutagenesis genes and elucidating the
activities of these gene products are essential steps in these
studies.
There is alWays a need for more effectively diagnosing,
preventing and treating cancer. This applies to the determi

With 0.2><SSPE, 0.1% SDS at 42° C. for 30 minutes
and then Wash in more stringent condition With

polynucleotide is a DNA. More preferably, the DNA

damage-induced mutagenesis pathWay similar to that in
yeast is operational in humans. Given the genetic complex
ity of the yeast mutagenesis pathWay, it is certain that more
human mutagenesis genes remain to be identi?ed. Since
mutations are the building blocks of human cancers, under

5%SDS and 50% formamide for 1 to 4 hours at 42°
C. and then hybridiZe in the same solution With
denatured labeled DNA probe and at 42° C. for

0.1><SSPE, 0.05%SDS at higher temperature, for
example, at 55° C. for 30 minutes. Preferably, the

in vitro (18). Apparently, the UmuC family of proteins are
involved in different mechanisms in the damage tolerance

homologues of the yeast RAD6 gene have been identi?ed:
HHR6A and HHR6B (19,20). Additionally, hREV3 has been
isolated as the human homologue of the yeast mutagenic
DNA polymerase Q (21,22). Thus, it is most likely that a

a polynucleotide Which encodes a homologous variant of
said polypeptide set forth in Table 1 having less than
about 750 amino acid changes; or
a polynucleotide sequence Which hybridiZes to the poly
nucleotide of Table 1 under the folloWing conditions:
prehybridiZe the membrane in solution of 0.25M
sodium phosphate, 0.25 M NaCl, 1 mM EDTA,

overnight. After hybridiZation, Wash the membrane

of error-free translesion DNA synthesis opposite a TT dimer

response to unrepaired DNA lesions during replication.
It is only very recently that the damage-induced mutagen
esis pathWay in humans has been investigated. TWo human

a polynucleotide Which encodes a variant of the polypep
tide set forth in Table 1 Wherein said variant has a

deoxycytidyl transferase activity;

belongs to the UmuC family of proteins (14). It possesses a

Yeast Rad30, an E. coli DinB homologue, is another member

and gene product described in the present application.

a pharmaceutically acceptable carrier or diluent.
It is an object of the invention to provide a method of
65

preventing tumor formation, comprising administering to a
person in need thereof, a prophylactic amount of an inhibitor

to human deoxycytidyl transferase. Preferably, the inhibitor

US 6,677,442 B1
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blocks transcription or translation of the deoXycytidyl trans
ferase gene. Also preferred is that the inhibitor blocks

ceRev1 sequence motif V is SEQ ID NO:15
atRev1 BRCT domain is SEQ ID NO:16
atRev1 sequence motif I is SEQ ID NO:17
atRev1 sequence motif II is SEQ ID NO:18
atRev1 sequence motif III is SEQ ID NO:19
atRev1 sequence motif IV is SEQ ID NO:20
atRev1 sequence motif V is SEQ ID NO:21
scRev1 BRCT domain is SEQ ID NO:22
scRev1 sequence motif I is SEQ ID NO:23
scRev1 sequence motif II is SEQ ID NO:24
scRev1 sequence motif III is SEQ ID NO:25
scRev1 sequence motif IV is SEQ ID NO:26
scRev1 sequence motif V is SEQ ID NO:27
spRev1 BRCT domain is SEQ ID NO:28
spRev1 sequence motif I is SEQ ID NO:29
spRev1 sequence motif II is SEQ ID NO:30
spRev1 sequence motif III is SEQ ID NO:31
spRev1 sequence motif IV is SEQ ID NO:32
spRev1 sequence motif V is SEQ ID NO:33
hRev1 BRCT domain is SEQ ID NO:34
hREV1 sequence motif I is SEQ ID NO:35
hREV1 sequence motif II is SEQ ID NO:36
hREV1 sequence motif III is SEQ ID NO:37
hREV1 sequence motif IV is SEQ ID NO:38
hREV1 sequence motif V is SEQ ID NO:39
FIG. 4.—EXpression of the REV1 gene in various human
tissues. First strand cDNA Was synthesiZed from polyA+
mRNA of various human tissues as indicated and normal

activity of the deoXycytidyl transferase protein by binding to
the protein, in Which case the preferred inhibitor is an
antibody, more preferably, a monoclonal antibody.
Another object of the invention is to provide a method for
treating or sloWing metastasis of a tumor, comprising admin
istering to a person in need thereof, a therapeutically effec
tive amount of an inhibitor to human deoXycytidyl trans
ferase.
Yet another object of the present invention is to provide a
method for preventing mutations in a person, comprising
administering to a person in need thereof, a therapeutically
effective amount of an inhibitor to human deoXycytidyl
transferase.
Table 1 describes the nucleotide and the deduced amino
acid sequences of the human REV1 (hREV1) gene. Nucle
otide sequence of the full-length hREV1 is shoWn in upper
case letters While the 5‘ and the 3‘ nontranslated regions are
shoWn in loWer case letters. The deduced amino acid

1O

15

sequence is shoWn by the single letter symbols of amino
acids. A mini open reading frame upstream of the hREV1
open reading frame is shoWn by the underline. The bold-type

indicates the putative polyadenylation signal.
BRIEF DESCRIPTION OF THE DRAWINGS

25

The present invention Will become more fully understood

from the detailed description given hereinbeloW, and the
accompanying draWings Which are given by Way of illus
tration only, and thus are not limitative of the present

invention, and Wherein;
FIG. 1.—Northern blot analysis of the human REV1

mRNA. A RNA sample prepared from normal human heart
tissue Was separated by electrophoresis and hybridiZed With
a 32P-labeled 59-mer oligonucleotide probe speci?c to the

iZed against the constitutive gene glyceraldehyde-3
phosphate dehydrogenase. A 360-bp DNA fragment
35

human REV1, as described in Materials and Methods. The
hybridiZed human REV1 mRNA Was visualiZed by autora
diography. The RNA siZe markers in kilobase are indicated
on the right.
FIG. 2.—Conservation betWeen the yeast and the human

visualiZed by ethidium bromide staining. The siZe markers
in bp are shoWn on the right.
FIG. 5.—The dCMP transferase activity of the human
REV1 protein. A. The DNA substrate used for dCMP
transferase assays. The 18-mer primer Was labeled With 32P
at its 5‘ end. B. Standard dCMP transferase assays Were

REV1 proteins. The yeast and the human REV1 protein
sequences Were aligned, and the signi?cantly conserved
regions of the proteins are schematically indicated by simi
larly shaded areas. The yeast Rev1 is shoWn at the top and
the human REV1 at the bottom. The amino acid sequence

45

identity and similarity Within each conserved region are
indicated.
FIG. 3.—Conserved structural domain and sequence
motifs of REV1 proteins from various biological sources.
Several sequence features Were identi?ed by aligning REV1
protein sequences of various organisms as indicated. Iden
tical amino acid residues are shaded. Similar amino acid

and 9). DNA siZe markers in nucleotides are indicated on the

right.
FIG. 6.—Transferase activity of the human REV1 protein
55

protein sequence motifs I to V. The REV1 sources are: ce, C.

elegans (GenBank accession number Z46812); at, A.

ing the site-speci?c uracil residue into an AP site by UDG

pombe (GenBank accession number AL035548); h, H. Sapi

treatment (UDG, +), the template (0.4 pmol) Was incubated

ens (GenBank accession number AF 151538).
BRCT domain is SEQ ID NO:10
sequence motif I is SEQ ID NO:11
sequence motif II is SEQ ID NO:12
sequence motif III is SEQ ID NO:13
sequence motif IV is SEQ ID NO:14

opposite a template AP site. A. The DNA substrates used for
dCMP transferase assays. The X position is a U Without
uracil-DNA glycosylase (UDG) treatment, or anAP site With
UDG treatment. The 17-mer primer Was labeled With 32P at

its 5‘ end. B. Complete conversion of uracil-containing
templates into AP site-containing templates. After convert

thaliana (GenBank accession number AC002342); sc, S.
cerevisiae (GenBank accession number M22222); sp, S.
ceRev1
ceRev1
ceRev1
ceRev1
ceRev1

performed in the reaction buffer containing a single dNTP
(A, C, G, or T, lanes 1—8) or all four dNTPs (N4, lanes 9 and
10) as described in Material and Methods. Protein samples
used Were 2 pl of the partially puri?ed human REV1 (lanes

2, 4, 6, 8, and 10), or 2 pl of an identically puri?ed protein
fraction from the rev1 deletion mutant cells (lanes 1, 3, 5, 7,

residues are shoWn as “+” in the consensus sequence.

Numbers in parentheses indicate gaps in the alignment.
BRCT domain, the BRCA1 C-terminus domain; I—V, REV1

corresponding to position +773 to +1132 of the human
REV1 cDNA Was ampli?ed by 35 cycles of PCR as
described in Materials and Methods. DNA products Were
separated by electrophoresis on a 1% agarose gel and

With 500 ng of E. coli endonuclease III at 37° C. for 30 min

65

(Endo III, +). Endo III cleaves DNA strand speci?cally at the
AP site. The reaction products Were separated by electro
phoresis on a 15% native polyacrylamide gel and visualiZed
by autoradiograpgy. Lanes 1 and 3 are controls Without any
treatment or With Endo III treatment only, respectively. C.

US 6,677,442 B1
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Standard dCMP transferase assays Were performed With 2 pl
of the partially puri?ed human REV1 in the reaction buffer
containing a single dNTP (A, C, G, or T, lanes 1—8) or all
four dNTPs (N4, lanes 9 and 10) as described in Material

Structural features of the human REV3 gene also suggest a

under normal groWth conditions human cells may contain
limited amounts of the mutagenesis proteins.

and Methods. +UDG, AP site template; —UDG, uracil
containing template. Lanes 11 and 12, control experiments

Wixlerr et al. (32) identi?ed a partial human cDNA Whose

loW-level expression (21,22). These features imply that

Most recently, by employing the yeast tWo-hybrid system

Without dNTPs in the reaction mixtures. DNA siZe markers

polypeptide interacts With the cytoplasmic domain of the
ot3A integrin subunit. This cDNA clone (alpha integrin
interacting protein 80, AIBP80) corresponds to the 2.6 kb of

in nucleotides are indicated on the right.

FIG. 7.—Pure human REV1 protein and its transferase
activity. To con?rm that the dCMP transferase activity is
intrinsic to the human REV1, the protein Was puri?ed to
apparent homogeneity as described in Materials and Meth

10

ods. A. The most pure Mono Q fraction Was separated by

electrophoresis on a 10% SDS-polyacrylamide gel using 10
pl of the sample. The His-tagged human REV1 protein Was

15

visualiZed by silver staining. Protein siZe markers (lane M)
in kDa are indicated on the left. B. The identity of the human
REV1 protein Was con?rmed by Western blot using a

monoclonal antibody against the His tag. C. A transferase
assay Was performed using the AP site-containing template

humans. In vitro, the human REV1 dCMP transferase func
20

human REV1 protein (2 pl, ~10 ng) in a reaction volume of
5 pl at 30° C. for 30 min. The reaction products Were
25

otides are indicated on the right.

DNA replication, regardless of the original base identity
30

35

including REV1 (27).

these observations clearly indicate the existence of a
40

mutagenesis in human cells requires the human REV3. The
45

originally identi?ed in the breast cancer suppressor protein
BRCA1 and subsequently found in some other proteins

interactions have been identi?ed. Additionally, REV1 pro
teins contain several conserved sequence motifs (I—V),
Which closely resemble those of E. coli UmuC-related

damage-induced mutagenesis pathWay in humans in
response to DNA lesions. Further supporting this
conclusion, Gibbs et al (21) shoWed that UV-induced

ous sources all contain an N-terminal BRCT domain. It Was

involved in cell cycle checkpoints, DNA repair, and
recombination, such as Rad9, p53-binding protein, XRCC1,
and DNA ligases III and IV (28—30). This structural domain
is important in protein-protein interactions (31). Thus, it is
likely that REV1 may interact With other proteins during
damage-induced mutagenesis, although none of the REV1

indicates that it is both a structural and a functional homo

logue of the yeast protein. Additionally, humans contain
highly conserved homologues of the yeast mutagenesis
proteins Rad6 (19,20) and Rev3 (21,22). Taken together,

have implicated at least 7 genes in this mutagenesis pathWay,

the human proteins. The REV1 protein is additionally found
in S. pombe, C. elegans, and A. thaliana, With signi?cant
sequence homologies among them. REV1 proteins of vari

needed for UV-induced mutagenesis in yeast (27), additional
function of the protein must be involved during mutagenesis
opposite other DNA lesions.
Yeast Rev1 is also a dCMP transferase (15). Thus, detec
tion of the dCMP transferase activity of the human REV1

mutagenesis pathWay in eukaryotes. Yeast genetic analyses
Applicants have isolated a full-length cDNA of the yeast
REV1 counterpart in humans. The REV1 protein is con
served from yeast to humans. Some regions share over 30%
identity and more than 50% similarity betWeen the yeast and

suggest that the damage-induced mutagenesis pathWay Will
previously residing at the AP site. Since REV1 is also

The yeast S. cerevisiae has served as the most informative

model organism in the studies of the damage-induced

tions ef?ciently opposite a template AP site. Thus, the human
REV1 transferase may play a critical role during mutagenic
translesion DNA synthesis opposite a template AP site in
vivo. Supporting this notion, Johnson et al. (33) recently
demonstrated that AP site-induced mutagenesis in yeast
requires the Rev1 protein. The results presented herein also
incorporate a C residue opposite an AP site during human

DETAILED DESCRIPTION OF THE
INVENTION

DNA damage-induced mutagenesis is an important cel
lular response to unrepaired DNA lesions during replication.
The biological outcome of this pathWay is enhanced cell
survival and increased mutations folloWing DNA damage.

discrepancies. This sequence Was localiZed by the Sanger
Centre betWeen 2q11.1 and 2q11.2, a region identical to
Applicants’ human REV1 chromosomal location.
Applicants found that the human REV1 protein is a dCMP
transferase capable of inserting a dCMP opposite a template
AP site. This activity provides evidence supporting a role of

the REV1 protein in damage-induced mutagenesis in

(see FIG. 6A) Without (lane 1) or With (lane 2) the pure
separated by electrophoresis on a 12% sequencing gel and
visualiZed by autoradiography. DNA siZe markers in nucle

the 3‘ end of our human REV1 cDNA, With a feW sequence

damage-induced mutagenesis pathWay is likely a fundamen
tal and major mechanism for generating mutations in
humans after DNA damage. Consistent With this hypothesis,
ubiquitous expression for both REV1 and REV3 (22) in
various human tissues Was observed.

Abbreviations

50

Abbreviations for amino acids used herein are conven

tionally de?ned as described hereinbeloW unless otherWise
indicated.
55

Three-letter

proteins (14).

One-letter

Amino Acid

abbreviation

symbol

Alanine

Ala

A

Arginine

Arg

R

Asparagine

Asn

N

Aspartic acid

Asp

D

Asparagine or aspartic acid

Asx

B

Cysteine
Diaminopropionic acid

Cys
Dpr

C

Glutamine
Glutamic acid

Gln
Glu

Q
E

Examination of the 5‘ untranslated region of the human
REV1 cDNA revealed the presence of an out-of-frame AT G
at nucleotide position —35 Which initiates an ORF of 12

codons and terminates at position +2. The stop codon of this
mini-ORE overlaps With the human REV1 initiator AT G
codon. The sequence context of this upstream ATG is close
to the consensus KoZak sequence (26). Thus, it is likely that
the translational ef?ciency of the human REV1 message
may be reduced by the presence of this upstream mini ORF.

60

65
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the polypeptide possesses the desired physical characteris
tics. Amino acid substitutions may also be made in the
sequences so long as the polypeptide possesses the desired

-continued
Three-letter

One-letter

Amino Acid

abbreviation

symbol

Glutamine or glutamic acid

Glx

Z

Glycine

Gly

G

Histidine
Isoleucine
Leucine

His
Ile
Leu

H
I
L

Lysine

Lys

K

Methionine
Ornithine

Met
Orn

M

Phenylalanine

Phe

F

Proline
Serine
Threonine

Pro
Ser
Thr

P
S
T

Tryptophan
Tyrosine

Trp
Tyr

W
Y

Valine

Val

V

physical and biochemical characteristics.
Sequence Identity at the Amino Acid Level
The variants of polypeptides contemplated herein should
possess more than 75% sequence identity (sometimes
referred to as homology, preferably more than 85% identity,
most preferably more than 95% identity, even more prefer
10

and/or speci?cally exempli?ed polypeptides or fragments
thereof described herein. To determine this homology, tWo
polypeptides are aligned so as to obtain a maximum match

using gaps and inserts.
15

applies to nucleic acid sequences and is used herein to mean
that the sequence is complementary to all or a portion of a

Speci?cally Exempli?ed Polypeptides

reference polynucleotide sequence.
Optimal alignment of sequences for comparison can be
conducted by the local homology algorithm of Smith and

the sequences exempli?ed in Table 1. The polypeptide can

be prepared by isolation from natural sources, polypeptide
synthesis by knoWn synthetic methods, or expression and

Waterman,Aa'd. Appl. Math, 2:482 (1981), by the homology
25

alignment method of Needleman and Wunsch, J. M01. Bi0l.,
48:443 (1970), by the search for similarity method of
Pearson and Lippman, Proc. Natl. Acad. Sci. USA, 85 :2444
(1988), or the like. Computer implementations of the above
algorithms are knoWn as part of the Genetics Computer

Variants of Polypeptide
Variants of the speci?cally exempli?ed polypeptides are
also encompassed by the present invention. Possible variants
include allelic variants and corresponding polypeptides from
other organisms, particularly other organisms of the same

Group (GCG) Wisconsin Genetics Software Package (GAP,
BESTFIT, BLASTA, FASTA and TFASTA), 575 Science
Drive, Madison, Wis.
“Percentage of sequence identity” is determined by com
paring tWo optimally aligned sequences over a comparison

species, genus or family. The variants may have substan
tially the same characteristics as the natural polypeptides.
The variant polypeptide Will possess one or more or all of

the folloWing physical and/or biological properties. Physical

TWo sequences are said to be “identical” if the sequence
of residues is the same When aligned for maximum corre

spondence as described beloW. The term “complementary”

The present invention relates to polypeptides comprising

recovery from a recombinant organism or by any other
convenient method.

ably more than 98% identity to the naturally occurring

35

WindoW, Wherein the portion of the sequence in the com

cytidyl transferase activity of the polypeptide that catalyzes

parison WindoW may comprise additions or deletions (i.e.
“gaps”) as compared to the reference sequence for optimal
alignment of the tWo sequences being compared. The per
centage identity is calculated by determining the number of

the insertion of a dCMP to a DNA primer opposite a

positions at Which the identical residue occurs in both

properties: ~140 kDa as determined by electrophoresis on a

10% SDS-polyacrylamide gel. Biological properties: deoxy

sequences to yield the number of matched positions, divid
ing the number of matched positions by the total number of
positions in the WindoW and multiplying the result by 100 to
yield the percentage of sequence identity. Total identity is

site
template
as determined
G residue by
or aatemplate
primer extension
apurinic/apyrimidinic
assay.
Primer extension assay: a DNA template or a DNA

oligonucleotide annealed With a 32P-labeled DNA primer
right before the template G residue or the template AP site.
Incubation of this DNA substrate With the polypeptide

45

containing a dCMP transferase activity under a standard

DNApolymerase assay buffer Will extend the labeled primer
one nucleotide longer Which is detected by a sequencing gel.
Inactivation or inhibiting this polypeptide through chemical,

then determined as the average identity over all of the
WindoWs that cover the complete query sequence.
Post-translational Modi?cation
Also included Within the scope of the present invention
are polypeptides or fragments or derivatives thereof Which
are differentially modi?ed during or after translation, e. g., by

biochemical, or molecular techniques Will lead to inhibition

glycosylation, proteolytic cleavage, phosphorylation,

of mutagenesis induced by ultraviolet (UV) and possibly

methylation, and amidation of glutamic acid, aspartic acid

some other DNA damaging agents. Mutagenesis is deter

and C-terminal carboxyl groups, lipid modi?cation, such as

mined by a standard mutation assay in human cells such as

prenylation and palmitoylation, and acetylation of the

the HPRT forWard mutation assay measuring mutations that

confer cells resistance to 6-thioguanine (Quan, T., Reiners,
J. J., Jr., Culp, S. J., Richter, P., and States, J. C. (1995) M01.

55

expressed as a fusion polypeptide or chimeric polypeptide
With a second polypeptide. The second polypeptide Will
usually impart an additional property or characteristic to the

Substitutions, Additions and Deletions
As possible variants of the above speci?cally exempli?ed
polypeptides, the polypeptide may have additional indi

fusion polypeptide Which is not possessed by the polypep
tide of the present invention.

vidual amino acids or amino acid sequences inserted into the

Fragments of Polypeptide

polypeptide in the middle thereof and/or at the N-terminal
and/or C-terminal ends thereof so long as the polypeptide
istics. Likewise, some of the amino acids or amino acid
sequences may be deleted from the polypeptide so long as

Fusion Polypeptides
The polypeptide of the present invention may be

Carcinog. 12, 91—102).

possesses the desired physical and/or biological character

N-terminus.

65

Fragments of the full length polypeptides such as pro
teolytic cleavage fragments Which contain at least one, and

preferably all, of the above-listed physical and/or biological
properties are also encompassed by the present invention.

US 6,677,442 B1
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The polypeptide or fragment or variant thereof usually has
a length of at least about 100 amino acids, usually less than

DNA and RNA
The invention encompasses DNA that codes for any one

1,300 amino acids, preferably betWeen 500 and 1,300 amino

of the above-described polypeptides including, but not lim
ited to, those shoWn in Table 1, including fusion
polypeptides, variants and fragments thereof. The sequence
of the cDNA Which has actually been sequenced is shoWn in

acids, more preferably betWeen 500 and 900 amino acids.

Signi?cantly featured regions: the BRCT domain from
amino acid 48 to amino acid 140 of the human REV1 protein
may be involved in interactions With other proteins.

Table 1. The present invention also includes cDNA as Well

REV1 motif I from amino acid 344 to amino acid 380 of

as genomic DNA containing or comprising the requisite

the human REV1 protein may be involved in the catalytic

nucleotide sequences as Well as corresponding RNA and
antisense sequences.

activity of the REV1 protein.

10

REV1 motif II from amino acid 415 to amino acid 450 of

Cloned DNA Within the scope of the invention also

the human REV1 protein may be involved in the catalytic

includes allelic variants of the speci?c sequences presented
in Table 1. An “allelic variant” is a sequence that is a variant

activity of the REV1 protein.
REV1 motif III from amino acid 523 to amino acid 570

from that of the exempli?ed nucleotide sequence, but rep
15

of the human REV1 protein may be involved in the catalytic

activity of the REV1 protein.

a population and perhaps ?xed in the population by standard
breeding methods, allelic variants can be produced by
genetic engineering methods. A preferred allelic variant is

REV1 motif IV From amino acid 580 to amino acid 620

of the human REV1 protein may be involved in the catalytic

activity of the REV1 protein.

20

REV1 motif V from amino acid 621 to amino acid 662 of

in FIG. 3.
25

polypeptide if it directs the expression of the polypeptide
referred to. The nucleic acid can be DNA or RNA. Unless
otherWise speci?ed, a nucleic acid sequence that encodes a

recombinant polypeptide should possess one or more of the
30

Recombinant polypeptide can be produced by a process
Which comprises culturing the transformed cell or microor

representative of mRNA, including untranslated portions
thereof.
35

ered polypeptide. In the processes for the synthesis of the

possible to substitute at least one base of the base sequence
40

processes are knoWn in the art and are described, for

DNA Modi?cation
45

and 18.
The polypeptide produced in this manner may be different
from natural polypeptide in that it may be free of other
polypeptides or materials Which occur in natural polypep

tide. The polypeptide produced by recombinant techniques

50

may also contain some small amounts of contaminating

materials from the microorganism, cells and/or fermentation
system in Which it Was produced. Thus, the present invention
is also directed to these neW or isolated polypeptides Which

are produced by recombinant DNA techniques.
Puri?cation of Recombinant Polypeptide

The DNA is readily modi?ed by substitution, deletion or
insertion of nucleotides, thereby resulting in novel DNA
sequences encoding the polypeptide or its derivatives. These
modi?ed sequences are used to produce mutant polypeptide
and to directly express the polypeptide. Methods for satu
rating a particular DNA sequence With random mutations
and also for making speci?c site directed mutations are
knoWn in the art; see eg Sambrook et al supra, Chapter 15.

HybridiZable Variants
The DNA molecule can comprise a nucleotide sequence
55 as shoWn in Table 1, or can comprise a nucleotide sequence
selected from the group consisting of a nucleotide sequence

that hybridiZes to a DNA molecule encoding the amino acid
sequence shoWn in Table 1 under salt and temperature
conditions equivalent to 5><SSC and 42° C. Preferably, the

Recombinant polypeptide can be recovered from cultures

by lysing the cells to release recombinant polypeptide Which
is present inside the cells. Initially, cell debris can be

of a gene by another kind of base Without causing the amino
acid sequence of the polypeptide produced from the gene to
be changed. Hence, the DNA of the present invention may
also have any base sequence that has been changed by

substitution in accordance With degeneracy of genetic code.

example, in Sambrook et al, Molecular Cloning: A Labora
tory Manual, 2nd Ed. c. 1989 by Cold Spring Harbor

Laboratory Press, Cold Spring Harbor, NY, Chapters 16, 17

Degenerate Sequences
In accordance With degeneracy of genetic code, it is

polypeptide, DNA Which encodes the polypeptide is ligated
into a replicable (reproducible) vector, the vector is used to
transform host cells, and the polypeptide is recovered from
the culture. Suitable replicable vectors Will be selected
depending upon the particular host cell chosen. Suitable

polypeptide includes both the transcribed strand and the
mRNA or the DNA representative of the mRNA. An “anti
sense” nucleic acid is one that is complementary to a strand

ganism described herein under conditions Which alloW

expression of the polypeptide, optionally recovering the thus
expressed polypeptide and optionally purifying the recov

phenotype of the organism. An expressed allele results in a
detectable change in the phenotype of the trait represented
by the locus.
A nucleic acid sequence “encodes” or “codes for” a

The present invention is also directed to a neW polypep

tide and a method for producing the polypeptide. The

above-described biological and/or physical properties.

one that is found in a naturally occurring organism, includ
ing a laboratory strain. Allelic variants are either silent or
expressed. A silent allele is one that does not affect the

the human REV1 protein may be involved in the catalytic
activity of the REV1 protein. All of these regions are shoWn

Production of Recombinant Polypeptide

resents the same chromosomal locus in the organism. In
addition to those Which occur by normal genetic variation in

60

separated by centrifugation. The remaining debris and the
supernatant are then repeatedly treated With solvents in
Which the cell debris are soluble but in Which the recombi
nant polypeptide is not soluble to thereby precipitate recom

DNA molecule is prehybridiZed in solution of 5><SSPE,
5><denhardt’s and 0.5%SDS, 50% formamide, 20—100 pig/ml
sonicated non-homologous DNA for 1 to 4 hours at 42° C.,
and then hybridiZed in the same solution but Without non

combined With other procedures including ?ltration, dialysis

homologous DNA and With denatured labeled DNA probe
for overnight at 42° C. After hybridiZation, the ?lter is
Washed tWice under less stringent conditions such as in

and/or chromatography to obtain a pure product.

2><SSPE, 0.1%SDS for 10 minutes at 42° C., a more

binant polypeptide. These procedures can be repeated and

65
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stringent condition is as follows: PrehybridiZation, hybrid

vector With T7 promotor, or pET vector With T7 promotor.
Other possible expression vectors are pTrc vector With trc

iZation and less stringent Wash are the same as above, but a
more stringent Wash condition is used such as: Wash in

promotor, pBAD vector With BAD promotor, pPROLar.A
and pPROTet.E vector, and pRIT2T vector.

1><SSPE, 0.1%SDS at 60° C. for 10 to 30 minutes and then
in 0.1><SSPE, 0.1%SDS at 60° C. for 10 minutes if neces
sary. The hybridized DNA codes for a polypeptide that has

Common prokaryotic host cells include bacteria such as
E.c0li.

one or more or all of the above-described physical and/or

Expression Systems Using Yeast Cells

biological properties. The present invention also includes
polypeptides coded for by these hybridiZable variants. See

In addition to prokaryotes, eukaryotic microbes such as
yeast cultures may be transformed With polypeptide encod

Chapters 11 and 12 of Sambrook et al, supra.

ing vectors. Saccharomyces cerevisiae, or common baker’s

Recombinant DNA Constructs

yeast, is commonly used among loWer eukaryotic host

Recombinant DNA constructs comprising one or more of
microorganisms, although a number of other strains are
the DNA or RNA sequences described herein and an addi
commonly available. Yeast vectors generally Will contain an
tional DNA and/or RNA sequence are also included Within
15 origin of replication from the 2 micron yeast plasmid or an
the scope of this invention. These recombinant DNA con
autonomously replicating sequence (ARS), a promoter, a
structs have sequences Which do not occur in nature or exist
DNA sequence coding for the desired polypeptide,
in a form that does not occur in nature or exist in association
sequences for polyadenylation and transcription termination
With other materials that do not occur in nature. The DNA
and a selection gene.

and/or RNA sequences described hereinabove are “operably
linked” With other DNA and/or RNA sequences. DNA

Suitable promoting sequences in yeast vectors include the

regions are operably linked When they are functionally

promoters for metallothionein, 3-phosphoglycerate kinase

related to each other. For example, DNA for a presequence
or secretory leader is operably linked to DNA for a polypep

or other glycolytic enZymes.

coding sequence if it is positioned so as to permit translation.

Other promoters, Which have the additional advantage of
transcription controlled by groWth conditions, are the pro
moter regions for alcohol dehydrogenase 2, isocytochrome
C, acid phosphatase, degradative enZymes associated With
nitrogen metabolism, and the aforementioned metallothion
ein and glyceraldehyde-3-phosphate dehydrogenase, as Well

Generally, operably linked means contiguous (or in close
proximity to) and, in the case of secretory leaders, contigu

tion. In constructing suitable expression plasmids, the ter

tide if it is expressed as a preprotein Which participates in the
secretion of the polypeptide; a promoter is operably linked
to a coding sequence if it controls the transcription of the
sequence; or a ribosome binding site is operably linked to a

as enZymes responsible for maltose and galactose utiliZa

ous and in reading phase.

mination sequences associated With these genes are also

ligated into the expression vector 3‘ of the polypeptide
coding sequences to provide polyadenylation of the mRNA

Vectors
The invention is further directed to a replicable vector

containing cDNA Which codes for the polypeptide and

35

Which is capable of expressing the polypeptide.

Expression Systems Using Vertebrate Cells

The present invention is also directed to a vector com

Interest has been great in vertebrate cells, and propagation
of vertebrate cells in culture (tissue culture) has become a
routine procedure. Examples of useful mammalian host cell

prising a replicable vector and a DNA sequence correspond
ing to the above described gene inserted into said vector. The
vector may be an integrating or non-integrating vector and

lines are VERO and HeLa cells, Chinese hamster ovary

is conveniently a plasmid.

(CHO) cell lines, and W138, BHK, COS-7 and MDCK cell
lines. Expression vectors for such cells ordinarily include (if
necessary) an origin of replication, a promoter located

Transformed Cells
The invention further relates to a transformed cell or

microorganism containing cDNA or a vector Which codes
for the polypeptide or a fragment or variant thereof and

upstream from the gene to be expressed, along With a
45

scriptional termination sequence.
The transcriptional and translational control sequences in
expression vectors to be used in transforming vertebrate

A plethora of suitable microbial vectors are available.
Generally, a microbial vector Will contain an origin of

cells are often provided by viral sources. For example,
commonly used promoters are derived from polyoma, Aden
ovirus 2, and most preferably Simian Virus 40 (SV40). The
early and late promoters are particularly useful because both

replication recogniZed by the intended host, a promoter
Which Will function in the host and a phenotypic selection

gene, for example, a gene encoding proteins conferring
antibiotic resistance or supplying an auxotrophic require
55

Vectors must contain a promoter Which is recogniZed by
to the intended host. Promoters often used in recombinant

site toWard the BglI site located in the viral origin of
replication is included.

DNA construction include the [3-lactamase (penicillinase)
and lactose promoter systems, a tryptophan (trp) promoter

An origin of replication may be provided either by

system and the tac promoter. While these are commonly
used, other knoWn microbial promoters are suitable. Details

construction of the vector to include an exogenous origin,
such as may be derived from SV40 or other viral (e.g.,

concerning their nucleotide sequences have been published,
enabling a skilled Worker to operably ligate them to DNA

a preferred vector is pGEX vector With tac promotor, pRSET

are obtained easily from the virus as a fragment Which also

contains the SV40 viral origin of replication. Smaller or

larger SV40 fragments may also be used, provided the
approximately 250 bp sequence extending from the Hind III

the host organism. This is generally a promoter homologous

encoding the desired polypeptide in plasmid vectors and the
DNA encoding the desired polypeptide. At the present time

ribosome binding site, RNA splice site (if intron-containing
genomic DNA is used), a polyadenylation site, and a tran

Which is capable of expressing the polypeptide.
Prokaryotic Host-Vector Systems

ment.

and termination.

Polyoma, Adenovirus, VSV, or BPV) source, or may be
65

provided by the host cell chromosomal replication mecha
nism. If the vector is integrated into the host cell
chromosome, the latter is often suf?cient.

US 6,677,442 B1
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Insect Cell Expression Systems

plants; and selecting a transformed plant Which expresses
the enZyme-encoding nucleotide sequence.

Insect cell expression systems can be used With the
present invention, as they are commonly described in
Ausubel et al., Current Protocols in Molecular Biology,

The encoding DNAs can be introduced either in a single
transformation event (all necessary DNAs present on the
same vector), a co-transformation event (all necessary

Green and Wiley, pub.(1994), Which is incorporated herein
by reference in its entirety.
Plant Cell Expression Systems

DNAs present on separate vectors that are introduced into

plants or plant cells simultaneously), or by independent
transformation events (all necessary DNAs present on sepa
rate vectors that are introduced into plants or plant cells

Plant Vectors

In plants, transformation vectors capable of introducing
nucleic acid encoding deoxycytidyl (dCMP) transferase are

10

easily designed, and generally contain one or more DNA
coding sequences of interest under the transcriptional con

trol of 5‘ and 3‘ regulatory sequences. Such vectors generally
comprise, operatively linked in sequence in the 5‘ to 3‘
direction, a promoter sequence that directs the transcription
of a doWnstream heterologous structural DNA in a plant;

single plant. Speci?c methods for transforming a Wide
variety of dicots and obtaining transgenic plants are Well
documented in the literature.

Successful transformation and plant regeneration have
15

USA, 84:5345 (1987)); barley (Hordeum vulgarae; Wan and
Lemaux, Plant Physiol., 104:37 (1994)); maiZe (Zea mays;

translated region that encodes a polyadenylation signal
20

transcription and the addition of polyadenylate nucleotides
to the 3‘ end of the mRNA encoding said protein. Plant
transformation vectors also generally contain a selectable
marker. Typical 5‘-3‘ regulatory sequences include a tran

scription initiation start site, a ribosome binding site, an

25

RNA processing signal, a transcription termination site,
and/or a polyadenylation signal.
Plant Promoters
Plant promoter sequences can be constitutive or inducible,
environmentally- or developmentally-regulated, or cell- or

30

tissue-speci?c. Often-used constitutive promoters include
the CaMV 35S promoter, the enhanced CaMV 35S

35

Useful inducible promoters include heat-shock promoters, a

nitrate-inducible promoter derived from the spinach nitrate
reductase gene, hormone-inducible promoters, and light
inducible promoters associated With the small subunit of
RuBP carboxylase and LHCP gene families. Examples of

40

useful tissue-speci?c, developmentally regulated promoters
include the [3-conglycinin 7S promoter and seed-speci?c
promoters. Plant functional promoters useful for preferential
expression in seed plastics include those from plant storage
protein genes and from genes involved in fatty acid biosyn
thesis in oilseeds. Examples of such promoters include the
5‘-regulatory regions from such genes as napin, phaseolin,

45

tional activity and tissue speci?city.
Plant Transformation and Regeneration
55

Deoxycytidyl Transferase

designed. Various strategies can be employed to introduce

these encoding DNAs to produce transgenic plants capable
of biosynthesiZing high levels of deoxycytidyl transferase
of interest. TWo or more transgenic plants, each con
taining one of these DNAs, can then be groWn and

cross-pollinated so as to produce hybrid plants contain
ing the tWo DNAS. The hybrid can then be crossed With
the remaining transgenic plants in order to obtain a
hybrid plant containing all DNAs of interest Within its
genome.

duce such vectors into plant protoplasts, cells, callus tissue,
leaf discs, meristems, etc., to generate transgenic plants,

2. Sequentially transforming plants With plasmids con
taining each of the encoding DNAs of interest, respec

tively.
60

mediated transformation, etc. In general, transgenic plants
comprising cells containing and expressing DNAs encoding
deoxycytidyl transferase can be produced by transforming

3. Simultaneously cotransforming plants With plasmids
containing each of the encoding DNAs, respectively.
4. Transforming plants With a single plasmid containing
tWo or more encoding DNAs of interest.

plant cells With a DNA construct as described above via any

of the foregoing methods; selecting plant cells that have

Production of Transgenic Plants Comprising Genes for

1. Transforming individual plants With an encoding DNA
50

US. Pat. No. 5,106,739), or to combine desired transcrip

been transformed on a selective medium; regenerating plant
cells that have been transformed to produce differentiated

Birch, Plant J., 2:409 (1992)); tall fescue (Festuca aruna'i
nacea; Wang et al, Bio/Technology, 10:691 (1992)); turf
grass (Agrostis palustris; Zhong et al, Plant Cell Rep., 13:1
(1993)); and Wheat (Triticum aestinum; Vasil et al, Bio/
Technology, 10:667 (1992); Weeks et al, Plant Physiol.,
102:1077 (1993); Becker et al, Plant J., 5:299 (1994)).

including:

constructed to enhance transcriptional activity (Hoffman,

including Agrobacterium-mediated transformation, particle
gun delivery, microinjection, electroporation, polyethylene
glycol-mediated protoplast transformation, liposome

tou et al, Bio/Technology, 9:957 (1991)); rye (Secale cere
ale; De la Pena et al, Nature, 325:274 (1987)); sorghum
(Sorghum bicolor; Cassas et al, Proc. Natl. Acad. Sci. USA;

(genomic DNAs, plasmid DNAs, cDNAs, or synthetic
DNAs) encoding deoxycytidyl transferase can be easily

desaturase, and oleosin. Seed-speci?c gene regulation is

Avariety of different methods can be employed to intro

(1992)); orchardgrass (Dactylic glomerata; Horn et al, Plant
Cell Rep., 7:469 (1988)); rice (Oryza saliva, including
indica and japonica varieties; Toriyama et al, Bio/
Technology, 6:10 (1988); Zhang et al, Plant Cell Rep., 7:379
(1988); Luo and Wu, Plant Mol. Biol. Rep., 6:165 (1988);
Zhang and Wu, Theor. Appl. Genet., 76:835 (1988); Chris

Plant transformation vectors capable of delivering DNAs

Zein, soybean trypsin inhibitor, ACP, stearoyl-ACP
discussed in EP 0 255 378. Promoter hybrids can also be

Rhodes et al, Science, 240:204 (1988); Gordon-Kamm et al,
Plant Cell, 2:603 (1990); Fromm et al, Bio/Technology,
8:833 (1990); KoZiel et al, Bio/Technology, 11:194 (1993));
oats (Avena saliva; Somers et al, Bio/Technology, 10:1589

90:11212 (1993)); sugar cane (Saccharum spp.; BoWer and

promoter, the FigWort Mosaic Virus (FMV) promoter, the

mannopine synthase (mas) promoter, the nopaline synthase
(nos) promoter, and the octopine synthase (ocs) promoter.

been achieved in the monocots as folloWs: asparagus

(Asparagus o?icinalis; Bytebier et al, Proc. Natl. Acad. Sci.

optionally a 5‘ non-translated leader sequence; a nucleotide
sequence that encodes a protein of interest; and a 3‘ non

Which functions in plant cells to cause the termination of

independently). Traditional breeding methods can subse
quently be used to incorporate the entire pathWay into a

65

5. Transforming plants by a combination of any of the
foregoing techniques in order to obtain a plant that
expresses a desired combination of encoding DNAs of
interest.
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Traditional breeding of transformed plants produced

mouse receives an identical quantity of hREV1 emulsi?ed

according to any one of the foregoing methods by successive
rounds of crossing can then be carried out to incorporate all

With incomplete Freund’s adjuvant. Approximately 10 days
after the second injection, serum sample are taken from each
mouse via the retro-orbital sinus and are assayed for anti

the desired encoding DNAs in a single homoZygous plant
line (NaWrath et al, 1994; PCT International Publication WO

hREV1 antibody activity by competitive ELISA immunoas

93/02187).
In methods 2 and 3, the use of vectors containing different
selectable marker genes to facilitate selection of plants
containing tWo or more different-encoding DNAs is advan

tageous. Examples of useful selectable marker genes include

10

those conferring resistance to kanamycin, hygromycin,

sulphonamides, glyphosate, bialaphos, and phosphinothri
cin.

Stability of Transgene Expression
As several overexpressed enZymes may be required to

15

say determination. For those mice shoWing the presence of
speci?c antibody in their serum, each is given a ?nal
immuniZation of the identical hREV1 again in 0.1 ml of PBS
injected into the tail vein 3 days prior to sacri?ce of the
animal.
The competitive ELISA immunoassay also is used to
determine the presence of speci?c antibodies against hREV1
in mouse sera (and subsequently to identify speci?c
hybridomas); these assays are modi?cations of methods
previously described in the art (Haugen et al., Proc. Natl.

produce optimal levels of deoxycytidyl transferase, the
phenomenon of co-suppression may in?uence transgene

Acad. Sci. U.S.A. 78:4124—4127 (1981); Groopman et al.,

expression in transformed plants. Several strategies can be

the procedure, hREV1 is dissolved in PBS at a concentration

employed to avoid this potential problem.
One commonly employed approach is to select and/or

Cancer Res. 42:3120—3124 (1982)). Brie?y summariZing
20

screen for transgenic plants that contain a single intact copy
of the transgene or other encoding DNA. Agrobacterium
mediated transformation technologies are preferred in this

regard.
Inclusion of nuclear scaffold or matrix attachment regions
(MAR) ?anking a transgene has been shoWn to increase the
level and reduce the variability associated With transgene
expression in plants. Flanking a transgene or other encoding
DNA With MAR elements may overcome problems associ
ated With differential base composition betWeen such trans

25

of 2.0 pig/ml and 50 ul of this ?uid mixture is added to each
Well of a polyvinyl microtiter plate and alloWed to incubate
for 2—4 hours at ambient temperature. Other Wells in the
microtiter plate receive 50 ul of gelatin in PBS at a concen
tration of 2 ug/ml and serve as controls. The ?uid in each
Well is then aspirated and each Well is Washed 3 times With

PBS With 0.05% (vol/vol) TWEEN 20. Subsequently, each
Well receives a PBS solution containing 0.2% gelatin and the
plates are alloWed to incubate for an additional hour at

30

genes or encoding DNAs and integration sites, and/or the
detrimental effects of sequences adjacent to transgene inte

ambient temperature. This procedure is designed to limit
non-speci?c binding of antibodies. The plates are then
Washed in PBS With 0.05% TWEEN 20 and 50 ul aliquots
of diluted mouse serum samples (or hybridoma medium)
plus appropriate competitor are added to each Well. To titer

gration sites.

the mouse sera, dilutions in PBS With 0.05 % TWEEN 20 are
The use of enhancers from tissue-speci?c or
prepared over a range from 1:100—1:51,200 in continuing
developmentally-regulated genes may ensure that expres 35 tWo-fold dilutions. The microtiter plates are then incubated
sion of a linked transgene or other encoding DNA occurs in
for 90 minutes at 37° C., after Which they are thoroughly

the appropriately regulated manner.
The use of different combinations of promoters, plastid
targeting sequences, and selectable markers for introduced
transgenes or other encoding DNAs can avoid potential
problems due to trans-inactivation in cases Where pyramid

ing of different transgenes Within a single plant is desired.
Finally, inactivation by co-suppression can be avoided by
screening a number of independent transgenic plants to
identify those that consistently overexpress particular intro
duced encoding DNAs. Site-speci?c recombination in Which

Washed With PBS+0.05% TWEEN 20. Speci?c antibodies
that become bound to the surface of each Well are detected
40

by adding 50 ul of a 1:1000 dilution of goat anti-mouse
IgG+IgM antibody coupled to alkaline phosphatase to each
Well folloWed by incubation of 90 minutes at 37° C. The
Wells in each plate are then reWashed With PBS With
TWEEN 20 plus a ?nal Wash With tap Water. 100 pl per Well

of 1.0 mg/ml p-nitrophenyl phosphate solution (Sigma)
45

prepared in 0.1M diethanolamine buffer, pH 9.8 then is
added and alloWed to react for 30 min. Quantitative mea

can be employed in order to insure the stability of transgene

surement of the p-nitrophenol reaction product is performed
by measuring the absorbance of the assay Well at 405
nanometers using a microtiter plate reader (Dynatech Labs).
The isotypes of the monoclonal antibodies (that is the
determination and identi?cation of different antibody heavy

expression in transgenic plants of the present invention.

chain class) are determined in a non-competitive ELISA

the endogenous copy of a gene is replaced by the same gene,

but With altered expression characteristics, should obviate

this problem.
Any of the foregoing methods, alone or in combination,

50

methodology using a commercially purchased kit for mouse

ImmuniZation of Mice and Isolation of Polyclonal Anti
bodies
Antibodies to hREV1 are made using conventional
methods, such as discussed in Ausubel et al. Current Pro

55

Preparation of Hybridomas and Isolation of Monoclonal

Antibody Producing Cells

tocols in Molecular Biology, Vol. 2, Supplement 18, Greene
publishing and John Wiley & Sons (1994), Which is incor
porated herein by reference in its entirety. An example of
hoW the antibodies are made is as folloWs. Female

Hybridomas and monoclonal antibodies to hREV1 are

prepared using conventional methods, such as discussed in
60

are immuniZed With hREV1 immunogen Which has been
dissolved in PBS and emulsi?ed With an equal volume of

complete Freund’s adjuvant. Using tWo groups of ?ve mice
of 50.0 ug of hREV1 (With adjuvant) in a ?nal volume of 0.2
ml PBS. At 4 Weeks and 8 Weeks post initial injection, each

Ausubel et al. Current Protocols in Molecular Biology, Vol.

2, Supplement 18, Green Publishing and John Wiley & Sons
(1994), Which is incorporated herein by reference in its
entirety. An example of hoW the hybridomas and mono

B6SJLF1/J (Jackson Labs), approximately 8 Weeks of age,

each, immuniZation is performed by intraperitoneal injection

immunoglobulin subtype identi?cation (Boeringer
Mannheim Company).

clonal antibodies are made is as folloWs. The female
65

B6SJLF1/J mice previously immuniZed With hREV1 in
complete Freund’s adjuvant are tested for production of
signi?cant anti-hREV1 serum titers using the competitive

US 6,677,442 B1
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by the polypeptide provides an obvious approach to

ELISA methodology as described above. Those mice shoW

targeted drug therapy.

ing high titers are sacri?ced and hybridomas prepared fol
lowing the procedures previously described in Marshak

3. It is also possible that an anti-sense sequence Which
binds to single stranded RNA corresponding to the gene

Rothstein et al., J. Immun, 122:2491—2497 (1979). The
myeloma cell line used for cell fusion are P3-X63/Ag8.653

of the present invention could be made Whereby the
anti-sense sequence Would bind to single stranded RNA
to prevent expression of the polypeptide.

cells Which Were maintained in Dulbecco’s Modi?ed Eagles

medium (hereinafter “DME” medium) supplemented With

Therapeutic Uses

20% (volume/volume) fetal calf serum, 2 mM L-Glutamine,
10 units/ml penicillin, 100 pig/ml streptomycin, and non
essential amino acids (Gibco). The mice are sacri?ced and

In the practice of the therapeutic methods of the present
10

spleen cell suspensions prepared using Hanks’ balance salt
solution buffered With 0.01M phosphate, pH 7.2 (hereinafter

“HPBS”).
The spleen cells from these mice are fused With P3-X63/
Ag8.653 myeloma cells using a modi?cation of the Gefter et

15

al. procedure (Somatic Cell Genet. 3:321 (1977)). Unless

invention, an effective amount of the active compound,
including derivatives or salts thereof, or a pharmaceutical
composition containing the same, as described beloW, is
administered via any of the usual and acceptable methods
knoWn in the art, either singly or in combination With
another compound or compounds of the present invention or

other pharmaceutical agents such as immunosuppressants,

stated otherWise, all centrifugations are preformed at 700
times gravity for 5 minutes at room temperature. Preferably,

antihistamines, corticosteroids, and the like. These com
pounds or compositions can thus be administered orally,

5><106 P3-X63/Ag8.653 myeloma cells and 2.5><107 immune

inhalation or by suppository, parenterally (e.g.,
intramuscularly, intravenously, subcutaneously or

spleen cells are combined in a round bottom plastic tube,
centrifuged, resuspended in 10 ml of serum free DME

sublingually, topically (e.g., on the skin or in the eyes), by
20

intradermally), or by inhalation, and in the form of either

medium and centrifuged again. The supernatant is carefully
discarded and the centrifuge tube tapped sharply to disperse

solid or liquid dosage including tablets, suspensions, and
aerosols, as is discussed in more detail beloW. The admin

the residual cell pellet. The cells are then exposed to 0.5 ml

of a 30% (volume/volume) solution of polyethylene glycol

25

istration can be conducted in single unit dosage form With
continuous therapy or in single dose therapy ad libitum. A

1000 (Baker Chemical Company) in serum free DME for 6

unit dose is de?ned as 1 to 3000 mg for a human patient.

minutes. During this 6 minute period, the cell suspension is

Useful pharmaceutical carriers for the preparation of the
pharmaceutical compositions hereof can be solids, liquids or
mixtures thereof; thus, the compositions can take the form of

gently centrifuged (150><gravity for 3 minutes). 4.0 ml of
serum free DME is then added to the cell pellet and the cells

again resuspended by tapping the tube. The contents of the

30

tablets, pills, capsules, poWders, enterically coated or other

tube are transferred to 100><17 mm Petri dishes and cultured

protected formulations (such as binding on ion exchange

in DME medium containing 20% fetal calf serum for 1 day.

resins or other carriers, or packaging in lipid or lipoprotein
vesicles or adding additional terminal amino acids), sus

The cells are then centrifuged again and resuspended in

groWth medium containing hypoxanthine, aminopterin and
thymidine (hereinafter “HAT medium”). 0.1 ml aliquots of

tained release formulations, erodible formulations, implant
35

the cells are then distributed into the Wells of ?at bottom

microtiter dishes, each aliquot containing approximately 105

suspensions, elixirs, aerosols, and the like.
Water, saline, aqueous dextrose, and glycols are preferred

P3-X63/Ag8.653 cells. After one Week’s incubation, 0.05 ml

of groWth medium containing only hypoxanthine and thy
midine (hereinafter “HT medium”) is added to each Well.
Cultures are screened for speci?c anti-hREV1 antibody
activity tWo Weeks post fusion using the competitive ELISA

liquid carriers, particularly (When isotonic) for injectable
40

solutions. The carrier can be selected from various oils

including those of petroleum, animal, vegetable or synthetic
origin, for example, peanut oil, soybean oil, mineral oil,

immunoassay technique described earlier.
Hybridomas secreting monoclonal antibodies of high
af?nity speci?c for hREV1 are groWn as ascites tumor cells

able devices or components thereof, microsphere

formulations, solutions (e.g., ophthalmic drops),

sesame oil, and the like. Suitable pharmaceutical excipients

include starch, cellulose, talc, glucose, lactose, sucrose,
45

in Scid mice Which has been previously injected With 0.5 ml

gelatin, malt, rice, ?our, chalk, silica gel, magnesium
stearate, sodium stearate, glycerol monostearate, sodium

pristane (Aldrich). The hybridomas groWing Within the mice
produce large quantities of speci?c monoclonal antibodies

chloride, dried skim milk, glycerol, propylene glycol, Water,
ethanol, and the like. The compositions may be subjected to

Which are harvested and collected as ascites ?uid from each
conventional pharmaceutical expedients such as steriliZation
mouse before it dies. The collected ?uid from these animals 50 and may contain conventional pharmaceutical additives

is pooled and either used directly in the immunoassays or

such as preservatives, stabiliZing agents, Wetting or emulsi

further puri?ed by saturated ammonium sulfate precipitation
and dialysed against PBS. Gross pathological examination

fying agents, salts for adjusting osmotic pressure, buffers,
and the like. Suitable pharmaceutical carriers and their
formulations are described in Martin, “Remington’s Phar

shoWs that all mice die as a result of Widespread tumor

invasion—that is groWth of the injected hybridoma cells.

Utility

55

The gene or DNA of the present invention and the

Such compositions Will, in general, contain an effective
amount of the active compound together With a suitable

polypeptide Which is coded by the DNA of the present
invention have various potential uses.

1. It is possible that the polypeptide of the present

60

invention is useful as a deoxycytidyl transferase. Thus,
into or contacted With a cell, it Will cause a speci?c

speci?cally enhances or inhibits the function of this

polypeptide. Knowledge of the precise sequence bound

amount of carrier so as to prepare the proper dosage form for
proper administration to the host.

In one preferred embodiment, the therapeutic methods of
the present invention are practiced When the relief of symp

if the polypeptide of the present invention is introduced

mutagenic bypass opposite an abasic site.
2. A drug might exist or might be developed Which

maceutical Sciences”, 15th Ed.; Mack Publishing Co., Eas
ton (1975); see, e.g., pp. 1405—1412 and pp. 1461—1487.

toms is speci?cally required or perhaps imminent; in another
preferred embodiment, the method hereof is effectively
65

practiced as continuous or prophylactic treatment.

In the practice of the therapeutic methods of the invention,
the particular dosage of pharmaceutical composition to be
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administered to the subject Will depend on a variety of
considerations including the nature of the disease, the sever

Construction of a Full-length Human REV1 cDNA

ity thereof, the schedule of administration, the age and
physical characteristics of the subject, and so forth. Proper
dosages may be established using clinical approaches famil

partial human REV1 cDNA sequences Were excised from

The insert cDNA from tWo )tgt11 clones With overlapping
the phage DNA With SalI restriction endonuclease and

subcloned into the plasmid vector pUC19M1. The resulting
plasmids, pWL269 and pWL270, contain the 3‘ half and the
5‘ half of the human REV1 cDNA, respectively. The full

iar to the medicinal arts. It is presently believed that dosages
in the range of 0.1 to 100 mg of compound per kilogram of
subject body Weight Will be useful, and a range of 1 to 100

mg per kg generally preferred, Where administration is by
injection or ingestion. Topical dosages may utiliZe formu
lations containing generally as loW as 0.1 mg of compound

length human REV1 cDNA Was constructed by ligating a 1.7
10

kb XbaI-SphI fragment from pWL270 and a 2.7 kb Sphl
SacI fragment from pWL269 into the SacI-XbaI sites of the

plasmid vector pUC19. The resulting recombinant plasmid,

per ml of liquid carrier or excipient, With multiple daily

pWL296, contained the full-length human REV1 cDNA.

applications being appropriate.

Isolation of Human REV1 Genomic Clones
A human REV1 clone from the human T cell cDNA
library Was excised in vivo from the ZAP Express vector in
E. coli XL1-Blue MRF‘ cells infected With a M13 helper

The invention being thus described, it is obvious that the
same can be varied in many Ways. Such variations are not to

be regarded as a departure from the spirit and scope of the
present invention, and all such modi?cations as Would be

15

phage. The resulting packaged phagemid particles Were used

obvious to one skilled in the art are intended to be included

to infect E. coli XLOLR cells to convert the phagemid into

Within the scope of the folloWing claims.

a double-stranded plasmid containing the human REV1
cDNA. The recovered plasmid Was then digested With
EcoRI restriction endonuclease, releasing the 0.8 kb human
REV1 cDNA insert (corresponding to the human REV1
cDNA position —178 to +646) from the plasmid vector. After
isolating it from an agarose gel, this cDNA fragment Was
used as the template to prepare 32P-labeled DNA probes by

EXAMPLES

20

Materials and Methods
Materials
Human bone marroW and leukocyte cDNA libraries in
)tgt11 Were purchased from Clontech Laboratories. Ahuman
T cell cDNA library in the ZAP Express vector and a human

placenta genomic DNA library Were purchased from Strat

25

clones from a human placenta genomic DNA library Were
screened With the human REV1 probes. TWo clones Were
isolated. The DNA inserts of approximately 20 kb each Were
subcloned into the NotI site of PCR-Script vector and

agene. E. coli uracil-DNA glycosylase Was obtained from
NeW England BioLabs. The vector pUC19M1 Was con

structed by Deepak Rajpal by adding BglII, EcoRV, NcoI,
and XhoI sites into the multiple cloning region of plasmid
pUC19 immediately after the HindIII site. The plasmid

randomly primed DNA synthesis. Approximately 2 million

30

partially sequenced.
Northern Blot Analysis of the Human REV1 mRNA

vector PCR-Script Was obtained from Stratagene. The E.
coli strains XL1-Blue MRF‘ and XLOLR Were purchased

Isolation of Human REV1 cDNA
Based on a human EST sequence (GenBank accession

A 59-mer oligonucleotide probe, corresponding to the
human REV1 cDNAposition —126 to —184, Was synthesized
and labeled With 32P at its 5‘ end by T4 polynucleotide
kinase. A human mRNA blot (Invitrogen) Was hybridiZed
With the probe in a buffer containing 50% formamide, 0.25
M NaCl, 0.25 M sodium phosphate, pH 7.2, 1 mM EDTA,

number AA029147), a 59-mer oligonucleotide (probe I),

and 5% SDS at 42° C. for 18 h. The blot Was Washed With

from Stratagene. The yeast strain CL1265rev1A (MATU.
rev1A arg4-17 leu2-3,112 his3-A1 trp ura3-52) Was derived
from CL1265-7C (1) by deleting the REV1 gene.

CATGGTACGAAAGCCTGGGGTCCTGTA
GAAACTGCAAAATTTGGAGGCCATGGAATTTG

35

15 mM NaCl, 1 mM sodium phosphate, pH7.4, and 0.1 mM
40

(SEQ ID N011), Was synthesiZed. After labeling With 32P at
its 5‘ end by T4 polynucleotide kinase, the probe Was used

an intensifying screen.

to screen human bone marroW and leukocyte cDNA libraries

by plaque DNA hybridiZation (23). Seventeen positive
clones Were isolated from approximately 1.6 million inde
pendent clones. Each insert cDNA Was either directly sub
cloned into the EcoRI site of pUC19 plasmid vector or

ampli?ed by PCR prior to plasmid subcloning using the )»
phage-derived primers, CGGCAGTACAATGGATTTCCTT
(SEQ ID N012) and CATCGCCATCTGCTGCAC (SEQ ID

45
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CAATCTCAGCGGAAGATCTGTGTATC

CATTAACATAGATGGCAACTC (SEQ ID N014) (probes
and

N017), Were used to amplify a 360 bp region of the human
REV1 cDNA. PCR reactions (20 pl) contained 0.4 ng
cDNA, 5 pmol each of the primers, 2 mM MgCl2, 20 mM

Tris-HCl, pH8.0, 50 mM KCl, 200 pM each of dATP, dCTP,
dGTP, and dTTP, and 1 unit of Taq DNA polymerase. After

CCACCCCATGTTTTCCAGCCAT

CATTTTCAGCTCGCTTCCTCCATCCAC

CTCGCCTCAT (SEQ ID N015) (probe III), Were synthe

sue cDNA panels Were purchased from Clontech Laborato
ries and used for PCR. TWo PCR primers,

CCCAGGAGGAGGATAAGGCTG (SEQ ID N016) and
GTCTTTGTAGGGTATTGACAAACTCAGTC (SEQ ID

dideoxynucleotide chain termination method on both

strands. The overlapping cDNA sequences yielded a partial

II)

Detection of the Human REV1 Expression
Expression of the REV1 gene in various human tissues
Was detected by RT-PCR. Poly(A) mRNA samples Were
isolated from various human tissues and used for ?rst strand
cDNA synthesis by reverse transcriptase. These cDNA

samples Were then normaliZed against glyceraldehyde-3
phosphate dehydrogenase cDNA. Such human multiple tis

N013). These cDNA inserts Were sequenced by the standard
cDNA sequence of 4.2 kb. Based on the 5‘ region of this
sequence, tWo 59-mer oligonucleotides, CATTAGTTTTCT

EDTA at 60° C. for 1 h. The hybridiZed human REV1
mRNA Was visualiZed by autoradiography at —80° C. With

60

heating at 94° C. for 30 sec, 35 cycles of ampli?cation Were
performed according to the folloWing conditions: 20 sec
denaturation at 94° C., 30 sec annealing at 60° C., and 45 sec

siZed and used to screen a human T cell cDNA library.
Approximately 40 cDNA clones Were isolated and their
insert sequences determined. Additional 5‘ sequence of the

extension at 68° C. Reaction products Were separated by
electrophoresis on a 1% agarose gel containing 0.5 pig/ml

complete sequence of a 4,255-bp human REV1 cDNA Was

ethidium bromide.
Puri?cation of the Human REV1 Protein
The 5‘ 2.3 kb open reading frame of the human REV1

generated.

cDNA Was ampli?ed from pWL296 by PCR, generating a

human REV1 cDNA Was obtained from some clones. Com

bining the 5‘ and 3‘ sequences of various cDNA clones, the

65
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DNA fragment ?anked by XbaI (added by the 5‘ PCR

and 0.05% xylene cyanol). The reaction products Were

primer) and HindIII sites. This DNA fragment Was cloned
into the XbaI-HindIII sites of the yeast expression vector
pEGLh6 (24). At its HindIII site, a 2 kb HindIII DNA
fragment containing the missing 3‘ end of the human REV1
Was then transferred from pWL296. The resulting plasmid
pEGLh6-hREV1 codes for the full-length human REV1
protein tagged With 6 histidine residues at its N-terminus.

resolved on a 12% polyacrylamide gel containing 8 M urea

and visualiZed by autoradiography. To obtain DNA substrate
containing an abasic site, the uracil-containing substrate (10
pmol) Was treated With 2 units of E. coli uracil-DNA
glycosylase at 37° C. for 60 min. Under this condition, the
site-speci?c uracil residue Was converted to an AP site in the

template.

Ayeast rev1 delta deletion mutant strain Was transformed

With pEGLh6-hREV1 for regulated human REV1 expres

10

Using the yeast Rev1 protein sequence, the non-redundant

sion under the control of the GAL1/10 promoter. Yeast cells
containing pEGLh6-hREV1 Were groWn in minimum
medium containing 2% sucrose to late logarithmic phase.
Expression of the human REV1 Was induced by diluting the

culture 10-fold in 16 LofYPG (2% Bacto-peptone, 1% yeast
extract, and 2% galactose) medium supplemented With

GenBank CDS database Was searched for its homologues. A

C. elegans hypothetical protein (ZK675.2) Was identi?ed.
15

sucrose to a ?nal concentration of 0.5% and groWth for 16

h at 30° C. Cells Were collected by centrifugation at 6,000><g
for 10 min at 4° C. and Washed in Water. After resuspending
in an extraction buffer containing 50 mM Tris-HCl, pH7.5,
600 mM KCl, 10% sucrose, 5 mM [3-mercaptoethanol, and

20

protease inhibitors (25), cells Were homogeniZed by Zirco
nium beads in a Bead-beater (BioSpec Products) for 15
25

cDNA sequence of the putative human REV1 gene Was
obtained.
To isolate the full-length human REV1 cDNA, a 59-mer
cDNA libraries Were screened. As a result, an additional 5‘

[3-mercaptoethanol and protease inhibitors). Bound proteins
imidaZole (100 ml). The REV1 protein fractions Were iden
ti?ed by Western blots using a monoclonal anti-His antibody
(Qiagene) and pooled. NaCl in the human REV1 sample Was
replaced With 50 mM KCl by passing the sample through a
G-25 Sephadex column. Some protein precipitates Were

searched a human EST clone (GenBank accession number
AA029147) Was identi?ed. Based on this clone, the EST
database Was searched again and tWo related EST clones

oligonucleotide probe Was synthesiZed and three human

0.5 M NaCl, 20 mM imidaZole, 10% glycerol, 5 mM
Were eluted With a linear gradient of 20 mM to 135 mM

Alignment of 710 amino acid residues shoWed 27% identity
and 44% similarity to the yeast Rev1. Thus, this C. elegans
protein is a homologue of the yeast Rev1. Using the C.
elegans REV1 protein sequence, the GenBank EST
(expressed sequence tag) database Was subsequently

(GenBank accession numbers AA393888 and T08134) Were
identi?ed. Combining the three EST sequences, a partial 3‘

pulses of 30 sec each. The clari?ed extract (~100 ml) Was

loaded onto a Ni2+-Sepharose column (10 ml) (Amersham
Pharmacia Biotech), folloWed by Washing the column With
100 ml of Ni buffer A(20 mM potassium phosphate, pH7.2,

Results
Cloning of the Human REV1 cDNA

sequence of the putative human REV1 gene Was obtained.
30

Subsequently, tWo additional 5 9-mer oligonucleotide probes
Were synthesiZed and used to screen the human cDNA

libraries. Forty cDNA clones Were isolated, the largest of
Which contained an insert of 4 kb. The 5‘ sequence of the
35

putative human REV1 gene Was generated after sequencing.
Finally, a cDNA clone containing both the 5‘ and the 3‘

formed, Which contained a signi?cant amount of the human

sequences Was reconstructed from partial cDNA clones

REV1 protein. The protein precipitates Were recovered by

(GeneBank accession number AF 151538). This cDNA
(4,255 bp) codes for a protein of 1,251 amino acid residues
With a calculated molecular Weight of 138,248 Da and p1 of

centrifugation at 20,000><g for 10 min at 4° C. and dissolved

in a buffer containing 20 mM potassium phosphate, pH7.2,
1 M KCl, 10% glycerol, and 5 mM [3-mercaptoethanol. This
sample containing partially puri?ed hREV1 Was used for

40

8.76. Upon searching the GenBank With Applicants’ protein
sequence, the yeast Rev1 Was identi?ed as its homologue

some activity assays. To further purify the human REV1

(PN=5><e_3°). Hence, Applicants’ cDNA clone codes for a
human homologue of the yeast mutagenesis protein Rev1.

protein, the soluble fraction from the G-25 Sephadex col

in P buffer (20 mM KH2PO4, pH7.4, 1 mM EDTA, 5 mM

Accordingly, this cDNA and its gene is referred to as the
human REV1.
The sequence context of the putative ATG start codon

B-mercaptoethanol, 10% glycerol, and protease inhibitors)

(CCACCATGA) in Applicants’ human REV1 clone matches

umn Was loaded onto a FPLC Mono S HR 5/5 column

(Amersham Pharmacia Biotech) that had been equilibrated

45

containing 50 mM KCl. The column Was eluted With a linear
Well With the KoZak consensus sequence (CCACCATGG),
KCl gradient from 50 mM to 500 mM in P buffer. The
Which is commonly found surrounding the mammalian ATG
human REV1 eluted at ~190 mM KCl. The KCl concentra 50 initiator codon (26). HoWever, the 5‘ untranslated region of
tion in the combined Mono S fractions Were reduced to 50
this human REV1 cDNA does not contain an in-frame
mM by gel ?ltration through a G-25 Sephadex column, and
termination codon. Furthermore, tWo cDNA clones con
subsequently loaded onto a FPLC Mono Q HR 5/5 column
tained an intron-like sequence 5‘ upstream of the position

(Amersham Pharmacia Biotech). Column equilibration and

—10, in Which the sequence context at the junction closely

elution conditions Were as in the Mono S chromatography. 55 resembles the consensus sequence of the 3‘ splicing site.
These observations raised the question Whether the full
The most pure human REV1 eluted at ~320 mM KCl.
length human REV1 Was indeed isolated. To ansWer this
Deoxycytidyl Transferase Assay
question, the siZe of the human REV1 mRNA Was ?rst
Deoxycytidyl transferase assays Were performed essen

determined by a Northern blot analysis. As shoWn in FIG. 1,

tially as described by Nelson et al. (15). The reaction

mixture (10 pl) contained 25 mM potassium phosphate
buffer, pH 7.4, 5 mM MgCl2, 0.1 mg/ml BSA, 10% glycerol,
5 mM dithiothreitol, 100 pM dNTP (dATP, dCTP, dGTP,
dTTP, or all four), 20 nM of 5‘ end 32P-labeled oligonucle
otide primer annealed to an oligonucleotide template as
indicated, and protein sample. After incubation at 30° C. for
30 min, reactions Were terminated With 7 pl of stop solution

(20 mM EDTA, 95% formamide, 0.05% bromophenol blue,

60
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the human REV1 mRNA Was estimated to be 4.5 kb. This is

in good agreement With the siZe of Applicants’ cDNA clone
(4.3 kb). Secondly, a human genomic library Was screened
using the human REV1 cDNA as the probe. TWo overlap
ping genomic clones Were isolated. Sequencing these clones
con?rmed the presence of the 5‘ splicing site and revealed
multiple termination codons upstream of the cDNA
sequence (GenBank accession number AF 153594). These
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results show that Applicants have isolated the full-length
cDNA of the human REV1. Additionally, the results indicate

Using a primed 40-mer DNA template (FIG. 5A), the
transferase activity of the partially puri?ed human REV1

that the ?rst exon of the human REV1 gene is non-coding.
In the human REV1 cDNA, an out-of-frame ATG codon
is located 32 nucleotides upstream of the initiator codon,

Which could potentially direct the synthesis of a polypeptide

Was assayed. As shoWn in FIG. 5B (lane 10), a transferase
activity Was detected that extended the 32P-labeled primer
by tWo nucleotides opposite the tWo template G residues. In
contrast, the control sample Without the human REV1 did

of 12 amino acids. Translation from this ?rst ATG codon
Would lead to an aborted human REV1 protein synthesis.
Thus, the translational ef?ciency of the human REV1 mRNA
may be reduced.
Conservation of REV1 Protein Sequences from Yeast to
Humans

not contain any detectable transferase activity (FIG. 5B, lane
9), indicating that the transferase activity is speci?c to the
human REV1 protein. To identify the nucleotides transferred
opposite the template G residues, the transferase assays Were
performed With dATP, dCTP, dGTP, or dTTP individually,
rather than all four dNTPs together. Only dCTP supported

1O

Sequence alignment betWeen the yeast and the human

the transferase activity (FIG. 5B, lane 4). Again, the trans

REV1 proteins revealed signi?cant homology (FIG. 2). Four
conserved regions Were identi?ed With amino acid sequence

ferase activity Was not detected With the control sample
15

Without the human REV1 protein (FIG. 5B, lanes 1, 3, 5, and

identities of 21—35% and similarities of 43—59% (FIG. 2).

7). The transferase activity Was not observed opposite a

After the human REV1 cDNA Was cloned, the A. thaliana

template A, C, or T (data not shoWn). Hence, the human

and the S. pombe REV1 homologues (GenBank accession

REV1 protein is a dCMP transferase, Which transfers dCMP

numbers AC002342 and AL035548, respectively) Were also

opposite a template G. Supporting this conclusion, the

identi?ed from the genomic sequencing projects. Again,

transferase activity co-puri?ed With the human REV1 as

protein sequence conservation Was found among these pro

revealed by Western blots during nickel-Sepharose column
chromatography (data not shoWn). In the control puri?cation

teins (FIG. 3). Comparison of various REV1 proteins
revealed a BRCT (BRCA1 C-terminus) domain at their

from rev1 deletion mutant extracts, none of the fractions

N-terminal regions and ?ve sequence motifs (FIG. 3).

contained the transferase activity (data not shoWn).

Chromosomal Localization of the Human REV1 Gene
Using the human REV1 cDNA as the probe, tWo human
REV1 genomic clones Were isolated from a library. One

25

To examine Whether the transferase activity of the human
REV1 functions opposite a template AP site, a site-speci?c

uracil-containing template Was prepared (FIG. 6A). Treat

clone contained a sequence tagged site (STS), EST164698

ment With uracil-DNA glycosylase completely converted the

(GenBank accession number G25709), upstream from the 5‘

uracil-containing templates into AP site-containing

end of the human REV1 gene. The distance betWeen this
STS and the 5‘ sequence of the human REV1 cDNA Was

coli endonuclease III (FIG. 6B, lane 2). Transferase activity

estimated to be 20 kb by PCR using either the genomic clone
or the total genomic DNA isolated from human placenta
(data not shoWn). The location of this STS Was assigned to
512.6 cR from the top of Chromosome 2 linkage group by

templates, as revealed by the AP site cleavage With the E.
of the human REV1 Was detected opposite the template AP

35

Radiation Hybrid Mapping of marker SGC33758 by the

site (FIG. 6C, lane 9). A template U also supported the
human REV1 transferase activity (FIG. 6C, lane 10). This is
also observed With the yeast Rev1 protein (15). HoWever,
unlike the yeast protein, Which utiliZes the template AP site
much more ef?ciently than the template U for its transferase
activity (15), the human REV1 uses both the template AP

Whitehead Institute/MIT Center for Genome Research. On

GeneMap’98, it Was further mapped to physical position:
355.80 cR3000 (P>3.00) betWeen reference intervals
D2S113—2S176 (115.3—120.8 cM). These markers are local
iZed betWeen 2q11.1 and 2q11.2 on the cytogenetic ideo

AP site or uracil, the transferase assays Were performed With

gram. Therefore, We conclude that the human REV1 gene is

only one deoxynucleoside triphosphate, dATP, dCTP, dGTP,

site and uracil efficiently (FIG. 6C, compare lanes 9 and 10).
To identify the nucleotides transferred opposite the template

located betWeen 2q11.1 and 2q11.2.

or dTTP. As shoWn in FIG. 6C (lanes 3 and 4), only dCTP

Expression of the REV1 Gene in Human Tissues
In yeast, the Rev1-involved mutagenesis pathWay is a
major mechanism for generating mutations after DNA dam
age. HoWever, it is not knoWn Whether this pathWay func
tions in various human tissues. Thus, the expression of the

supported the human REV1 transferase activity opposite the
45

template AP site or uracil. These results shoW that the human
REV1 protein is a template-dependent dCMP transferase
that is active opposite a template G, U, or AP site.
The yeast REV1 gene had been deleted from the host cells

used for the human REV1 expression and puri?cation. Thus,

REV1 gene Was examined as an indication of the importance

of this putative mutagenesis pathWay in various human

the yeast Rev1 could not have contaminated the human

tissues. As shoWn in FIG. 4, the human REV1 expression

REV1 protein preparations. Nevertheless, to provide further

Was detected by RT-PCR in all of the 16 tissues examined.
Hence, We conclude that the REV1 gene is ubiquitously

support to the conclusion that the human REV1 is a dCMP

expressed in humans.

ity (FIGS. 7A and 8B). Again, a transferase activity opposite

The Human REV1 Protein is a dCMP Transferase

transferase, the protein Was puri?ed to apparent homogene
55 an AP site Was observed With the pure human REV1

preparation (FIG. 7C). Additionally, When the transferase

The yeast Rev1 protein possesses a deoxycytidyl trans
ferase activity, Which transfers a dCMP residue to the 3‘ end
of a DNA primer opposite a template G or an AP site (15).
To determine Whether the human REV1 protein is a dCMP

assay Was performed opposite a template G using the pure
human REV1 protein, the dCMP transferase activity Was
detected (data not shoWn). These results shoW that the
observed dCMP transferase activity is associated With the

transferase, the protein Was ?rst partially puri?ed and then

human REV1 protein.
Whereas particular embodiments of this invention have

the dCMP transferase activity Was assayed. To facilitate

detection and puri?cation of the human REV1, the protein

been described above for purposes of illustration, it Will be

Was tagged With six histidine residues at its N-terminus, and
Was expressed in yeast rev1 deletion mutant cells. The

tagged human REV1 Was puri?ed by af?nity chromatogra
phy on a nickel-Sepharose column. As a control, rev1
deletion mutant extracts Were used for identical puri?cation.

evident to those persons skilled in the art that numerous
65

variations of the details of the present invention may be
made Without departing from the invention as de?ned in the

appended claims.

